Biotronik’s CLS technology shown to reduce fainting in syncope patients

Biotronik has announced new clinical trial data demonstrating the effectiveness of its Closed Loop Stimulation (CLS) among pacemaker patients with vasovagal syncope.

The company's exclusive rate-responsive CLS technology was evaluated in a clinical study called SPAIN, and has been shown to reduce fainting in pacemaker patients with vasovagal syncope by a factor of seven.

For this trial, 54 patients aged 40 or older were recruited from 11 medical centres in Spain and Canada. Syncope patients represent a challenging population, for whom no other treatment options exist.

If the findings are confirmed by larger studies such as the ongoing BioSync CLS trial, Biotronik is hoping that international guidelines will be amended to recommend CLS pacing in this patient group.

Albert Panzeri, vice-president at Biotronik, said: "With the BIOSync CLS trial, Biotronik is doing its part to gather further clinical evidence with the potential to make a significant difference in these patients' lives."

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.